Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥18 years old.~* Patients with histologically confirmed unresectable Stage III or Stage IV metastatic melanoma who have not been previously treated with a selective BRAF inhibitor.~* Presence of a BRAF V600 mutation in the tumor tissue using the cobas BRAF mutation assay or comparable standard of care methodology.~* Measurable disease per RECIST v. 1.1 criteria.~* ECOG performance status 0 or 1.~Exclusion Criteria:~* Radiation therapy within 14 days of C1D1.~* Investigational drug use within 28 days of C1D1.~* Patients with active CNS lesions are excluded (i.e., those with radiographically unstable, symptomatic lesions). However, patients treated with stereotactic therapy or surgery are eligible if they remain without evidence of disease progression in the brain for ≥3 weeks.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose extension cohort (Type: EXPERIMENTAL): Patients will take PLX3397 and vemurafenib at the recommended phase 2 dose. This will be determined by the tolerability and safety of these drugs in the previous 3 cohorts.
- Cohort 3 (Type: EXPERIMENTAL): Patients will take 1000mg/day of PLX3397 and 960mg BID of vemurafenib
- Cohort 2 (Type: EXPERIMENTAL): Patients will take 800mg/day of PLX3397 and 960mg BID of vemurafenib
- Cohort 1 (Type: EXPERIMENTAL): Patients will take 800mg/day of PLX3397 and 720mg BID of vemurafenib

Based on this trial design, predict the completion outcome and termination type (if applicable).